Momenta Pharmaceuticals, Inc. - Science

Novel Therapies

Clinical Pharmacology & Therapeutics publication containing the full data from the Phase 1 Study Data for Anti-FcRn Antibody, nipocalimab (M281), entitled: Nipocalimab (M281), an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics and Safety across the Full Range of IgG Reduction in a First-In-Human Study
A Therapeutic FcRn Blocking Antibody for Rapid Clearance of IgG and IgG Autoantibodies in Immune Cytopenias and other Autoimmune Diseases View Poster
Targeting the Neonatal Fc Receptor (FcRn) to Mediate Autoantibody Clearance in IgG-driven Autoimmune Disease View Poster

Hyper-sialylated IgG M254, an Innovative Therapeutic Candidate, Evaluated in Healthy Volunteers and Patients With Immune Thrombocytopenia Purpura: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics --- Santiago Arroyo, MD, PhD; Renger G. Tiessen, MD, PhD; William S. Denney, PhD; Jim Jin, MS; Mattheus Paulus (Thijs) van Iersel, MD; Heidi Zeitz, MEd, CCRA; Anthony M. Manning, PhD; Martin R. Schipperus, MD, PhD; James B. Bussel, MD; American Society of Hematology Annual Meeting, December 7, 2019.View Poster
Washburn N, Schwab I, Ortiz D, Bhatnagar N, Lansing J, Medeiros A, Tyler S, Mekala D, Cochran E, Sarvaiya H, Garofalo K, Meccariello R, Meador J, Rutitzky L, Schultes B, Ling L, Avery W, Nimmerjahn F, Manning A, Kaundinya G and Bosques C. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.PNAS 2015 112 (11) E1297-E1306; published ahead of print March 2, 2015, doi:10.1073/pnas.1422481112
PEGS - Boston, 2014. Embracing EmComplexity: Understanding IVIgto Rationally Design Novel TherapeuticsView PPT

Ortiz DF, Lansing JC, Rutitzky et al. Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors. Sci. Transl. Med. 8, 365ra158 (2016).
PEGS - Boston, 2015. Selective Modulation of Fc Receptors for Improved Therapy of Orphan Autoimmune Diseases: Lessons from IVIg View PPT